Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline

Dapagliflozin is a highly selective sodium-glucose cotransporter 2 inhibitor associated with stabilization of estimated glomerular filtration rate (eGFR); reductions in glycated hemoglobin (HbA1c), systolic blood pressure, body weight, and albuminuria; and a small and consistent increase in hematocr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Data Brief
Hlavní autoři: Stefánsson, Bergur V., Heerspink, Hiddo J.L., Wheeler, David C., Sjöström, C. David, Greasley, Peter J., Sartipy, Peter, Cain, Valerie, Correa-Rotter, Ricardo
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2021
Témata:
Data Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8255174/
https://ncbi.nlm.nih.gov/pubmed/34258337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dib.2021.107237
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky